What we do

We build a simple, safe and effective scalable Heart Ablation platform that will be able to serve the segments of the market that are not being served today.


The Aqua technology platform is proven and  medical devices based on that platform have passed FDA approvals, animal and FIH studies.


The Aqua Heart heart ablation catheter is designed for a secure procedure using the latest available engineering and medicaldevice technologies.

The catheter might be used by interventional cardiologists in a regular catheter lab.


The technology is simple, automated, safe and effective. More cardiologists will be able to treat more patients.

Democratizing Heart Ablation for a Larger Population

Atrial Fibrillation is a potentially deadly condition, yet only 10% of patients receive curative treatment today. At AquaHeart, we are on a mission to change that. Our groundbreaking high-energy, short-duration, single-shot Pulmonary Vein Isolation technology is paving the way for accessible treatment on a global scale.

By developing a solution that can be applied faster, safer, and more easily, we are addressing a large unmet need of untreated Atrial Fibrillation patients. With AquaHeart, heart ablation is no longer limited to a select few—it is now within reach for all patients and interventional cardiologist.

Preventing Stroke: Combating Atrial Fibrillation 

Atrial Fibrillation poses a significant risk of stroke, affecting up to 15% of individuals due to blood clot formation in the left atrial heart chamber. Unfortunately, current Pulmonary Vein Isolation treatment options only reach < 10% of those in need. This stark reality drove us to develop a technology that could be applied to a larger population. At AquaHeart, we firmly believe in democratizing Pulmonary Vein Isolation treatment for Atrial Fibrillation. By utilizing our "over the guidewire" technique we provide swift, effective, and safe single-shot Pulmonary Vein Isolation, we are making ablative atrial fibrillation therapy more accessible and efficient.

Powered by Proven Aqua RF Vapor Technology and Developed by Electrophysiology Leaders

AquaHeart is built upon the success of the Aqua Group of companies. Our core platform technology has been used in multiple FDA-approved medical devices and is protected by a strong patent portfolio and serves as a testament to our commitment to quality and innovation. We collaborate with global leaders in the field of cardiac ablations and medical device engineering to create a globally applicable, safe, intuitive, and user-friendly single-shot, high-energy, short duration cardiac ablation system. Together, we are pushing the boundaries of what is possible in cardiovascular care.

Simplicity, Safety, and Accessibility 

At AquaHeart, we believe in unlocking accessibility through simplicity and safety. Our groundbreaking technology eliminates the need for complicated mapping procedures, streamlining the heart ablation process. Our real-time treatment monitoring and feedback reduces reliance on specialized electrophysiologist and costly catheter laboratories, allowing our safe, simple, and intuitive technology to be implemented in a wider range of hospitals. This will allow more patients access to and benefit from our treatment, leading to improved public health outcomes, save health-care cost and enhanced patient quality of life.

Join the AquaHeart Community

We invite you to join us on this extraordinary journey towards a future free from the constraints of atrial fibrillation. Together, we can revolutionize the landscape of cardiac care and empower patients around the world. Explore our website to learn more about AquaHeart, our pioneering PVI therapy, and the positive impact it can have on your life.

Contact us today to be a part of the AquaHeart revolution. Together, we can rewrite the story of atrial fibrillation treatment and pave the way for a healthier, brighter tomorrow.

Visit AquaHeart at www.aquahrt.com and discover the future of atrial fibrillation therapy today!

The superior Solution for a mature Market

Existing Atrial Fibrillation (AF) Ablation Market globally $8 Billion (Stiefel 8/22 ) with 15 % CAGR. However: >90 % Patients are not treated with ablation.

  • Aqua Heart is the only single shot High Power Short Duration (HPSD) tool, combining the best of RF and Balloon applications
  • Thermal Ablation like ours is very well understood by Electrophysiologists
  • Easy to use and automated processes fulfills the needs of high-volume centers as well as the not so experienced interventionalists. Potential for an automated closed loop feedback system will optimize therapy for each PV.


Attractive CAGR >15%

  • Currently most used technologies are RF (appr. 70%) and Cryo (about 25%), in the future potentially PFA and STEAM
  • Market dominators are J&J, Abbott, Medtronic and Boston Scientific, in aggregate >90% market share